Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
about
Nanotherapeutics for multiple myeloma.Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoVPerspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
P2860
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@en
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@nl
type
label
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@en
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@nl
prefLabel
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@en
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
@nl
P2860
P356
P1476
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
@en
P2093
Julia Hambach
Peter Bannas
P2860
P356
10.3389/FIMMU.2017.01603
P577
2017-11-22T00:00:00Z